Boehringer, Eli Lilly get FDA fast track status for Jardiance to treat chronic kidney disease

This article was originally published here

The designation will help investigate the efficacy of Jardiance to minimise the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease. Jardiance, a

The post Boehringer, Eli Lilly get FDA fast track status for Jardiance to treat chronic kidney disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply